Robert Duggan, a member of the board of directors of Summit Therapeutics Plc, has been appointed executive chairman to help guide development of the company’s candidate antibiotics. Glyn Edwards continues as an executive director of the company and its chief executive officer.
Mr Duggan is a serial US-based entrepreneur who currently is CEO of Duggan Investment Inc. He is also chairman of the board of Pulse Biosciences Inc. He was formerly chairman and CEO of the cancer drug developer Pharmacyclics Inc, which was sold to AbbVie Inc in 2015.
Summit Therapeutics announced the appointment on 26 February 2020.
Copyright 2020 Evernow Publishing Ltd